Skip to main content

Advertisement

Table 2 Clinical data of patients with lSSc, lcSSc and dcSSca

From: Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study

Subset lSSc (n= 7) lcSSc (n= 29) dcSSc (n= 17)
Mean age, yr (± SD) 51 ± 16 51 ± 13 55 ± 8,0
Female/male, n 6/1 21/8 9/8
Median disease durationb (rangec) 2 (2 to 21) 6 (0 to 35) 2 (0 to 12)
Median mRSS (range) 0 (0 to 0) 4 (0 to 14) 21 (4 to 27)
Median local skin score dorsal forearm (range) 0 (0 to 0) 0 (0 to 2) 1 (0 to 3)
ACR criteria, n 0 14 17
ANA, n    
   Topoisomerase I 0 5 8c
   Centromere 6 14 3c
   RNA polymerase III 0 1 3
   U1-RNP 0 3 0
  1. aACR, American College of Rheumatology; ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; lSSc, limited systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; mRSS, modified Rodnan skin score; U1RNP, U1-ribonucleic protein; bdisease duration from first non-Raynaud's phenomenon symptom; cone patient had both anticentromere and anti-topoisomerase I antibodies. crange denotes the full interval between the smallest and largest values